A Winning New Combination? Toward Clinical Application in Oncology

Area of Science:

• Oncology
• Immunology
• Gene Therapy

Background:

• Immunotherapy, utilizing CTLA-4 and PD-1 inhibitors, has shown significant success in treating various cancers like melanoma and lung cancer.
• Understanding tumor-immune system interactions is crucial for advancing oncology research and developing novel therapeutic strategies.
• Tumors can evade the host immune system by altering antigen presentation and avoiding detection, necessitating innovative treatment approaches.

Approach:

• This review details the history, breakthroughs, and future prospects of three gene therapy treatment modalities: immunotherapy, oncolytic virotherapy, and gene transfer.
• It examines the relationship between anti-cancer immune responses and the mechanisms underlying immunotherapy resistance.
• The review covers combination therapies approved by the FDA and their current clinical performance.

Key Points:

• Immunotherapies, such as adoptive cell therapy (ACT) and immune checkpoint blockade (ICB), have revolutionized cancer care, offering hope for previously incurable conditions.
• Gene therapy offers cutting-edge medicines poised to significantly reduce cancer mortality.
• The article provides a comprehensive overview of various treatment modalities, including cytokines, vaccines, innate immune modifiers, ACT, and virotherapy.

Conclusions:

• Gene therapy modalities, particularly immunotherapy and oncolytic virotherapy, represent a paradigm shift in cancer treatment.
• Continued research into tumor-environment interactions and immune evasion mechanisms will drive the development of more effective cancer therapies.
• The integration of diverse therapeutic strategies holds promise for improving patient outcomes and reducing cancer-related mortality.